Metformin regulates AMPK/SREBP-1 pathway and its clinical application
10.12092/j.issn.1009-2501.2022.09.012
- Author:
Xin WANG
1
;
Chen WU
1
;
Jinjun KAI
1
;
Xuejie LIANG
1
;
Yingxuan CHANG
1
;
Weiying LIU
2
Author Information
1. First Clinical Medical College, Lanzhou University
2. Department of Respiratory and Critical Care Medicine, First Hospital, Lanzhou University
- Publication Type:Journal Article
- Keywords:
AMPK;
glucose;
lipid synthesis;
metformin;
sterol regulatory element binding protein-1
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2022;27(9):1049-1054
- CountryChina
- Language:Chinese
-
Abstract:
Metformin is one of the commonly used hypoglycemic drugs in clinical practice. In addition to hypoglycemia, there are a variety of medical biological values that have been constantly discovered and attracted much attention. In recent years, studies have shown that metformin through activation of AMPK inhibition of sterols regulating element binding protein 1 (SREBP-1) reduce lipid synthesis, in the treatment of liver steatosis, improve insulin sensitivity, prevention Metformin is one of the commonly used hypoglycemic drugs in clinical practice. In addition to hypoglycemia, there are a variety of medical biological values that have been constantly discovered and attracted much attention. In recent years, studies have shown that metformin through activation of AMPK inhibition of sterols regulating element binding protein 1 (SREBP-1) reduce lipid synthesis, in the treatment of liver steatosis, improve insulin sensitivity, prevention of atherosclerosis and cardiovascular dysfunction, tumor, polycystic ovary syndrome and adjuvant therapy of COVID-19 aspects play a role. Therefore, this article reviews the possible mechanism and clinical application of metformin in regulating glucose and lipid metabolism by inhibiting SREBP-1 through activating AMPK.
